Last updated: May 2026 — Siddons Law Firm tracks active MDLs each month. Updates posted on the first business week.
The Big Picture
The Ozempic / GLP-1 federal MDL (In re: Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation, MDL No. 3094) is now consolidated in the Eastern District of Pennsylvania before Judge Pratter. The MDL covers Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, Saxenda, and Victoza. As of mid-2026, more than 1,000 cases are pending in the MDL with thousands more expected as awareness of the link to gastroparesis, ileus, and intraoperative pulmonary aspiration grows.
What Has Happened Recently
- Bellwether selection underway. The court is in the process of selecting bellwether cases focused on gastroparesis and severe gastrointestinal injuries. The first bellwether trial is expected in late 2026 or early 2027.
- Label updates continue to expand. The FDA continues to require updated warnings about gallbladder disease, intraoperative pulmonary aspiration, and ileus. Each label change marks a date after which manufacturers can argue they discharged their duty to warn — making early-use cases stronger.
- NAION (sudden vision loss) cases are accumulating. Following the Harvard study linking semaglutide to NAION, plaintiffs with documented NAION diagnoses have begun filing in significant numbers.
- Compounded semaglutide remains excluded. The MDL continues to limit eligibility to brand-name medications. Cases where the patient used compounded semaglutide from a compounding pharmacy generally do not qualify.
Who Qualifies for an Ozempic / GLP-1 Case
Our firm is currently accepting cases that meet all of these criteria:
- Used a brand-name GLP-1 (Ozempic, Wegovy, Rybelsus, Mounjaro, Trulicity, Zepbound, Saxenda, or Victoza) for at least 30 days.
- Diagnosed and medically treated for one of the following: gastroparesis, ileus, intestinal obstruction, intraoperative pulmonary aspiration, gallbladder removal, NAION, DVT or PE, kidney injury from dehydration, severe persistent vomiting, or wrongful death.
- Usage began before the FDA label-update cutoff for the relevant injury (March 2022 for Ozempic gallbladder claims, January 2024 for Mounjaro pulmonary aspiration, January 2025 for Ozempic severe GI reactions).
- No prior abdominal surgery on or near the stomach affecting the vagus nerve.
What This Means for People Considering a Case
Bellwether trials drive settlement values. Once the first GLP-1 verdicts are returned, the MDL settlement framework typically follows within 12–24 months. Cases filed BEFORE that settlement framework is announced tend to recover more than cases filed after — and qualification windows tighten as more label changes are issued.
If you used a brand-name GLP-1 for at least 30 days and were diagnosed with any of the qualifying injuries, the practical answer is: don’t wait. Statutes of limitations are running, and label cutoffs continue to shift the goalposts.
Take our full GLP-1 intake screening →
Or call (610) 255-7500 for a free case review. No fee unless we recover.
Disclaimer: This post summarizes the public status of pending litigation. Nothing in this post is legal advice for any specific claim. The MDL status, label dates, and acceptance criteria are subject to change. Verify before relying.
